Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.47 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.46 |
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
| ▸ | TYK2 | P29597 | 1/20 | 0.43 |
| ▸ | ROCK2 | O75116 | 4/20 | 0.42 |
| ▸ | ROCK1 | Q13464 | 4/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | BCHE | P06276 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.41 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.41 |
| ▸ | GSK3A | P49840 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL60777 | 1.00 | GAA (0.47) | GAAMDM2TAAR1JAK2TYK2 | |
| SCHEMBL60778 | 1.00 | GAA (0.47) | GAAMDM2TAAR1JAK2TYK2 | |
| SCHEMBL10434559 | 0.87 | KDM4E (0.49) | GAATAAR1ROCK2ROCK1KDM4E | |
| SCHEMBL5954539 | 0.85 | TSHR (0.58) | L3MBTL1LMNA | |
| SCHEMBL5954535 | 0.85 | TSHR (0.58) | L3MBTL1LMNA | |
| SCHEMBL2029540 | 0.84 | SLC7A5 (0.50) | KDM4EPTGS2 | |
| SCHEMBL10434510 | 0.84 | LMNA (0.52) | GAATAAR1KDM4ELMNAHTT | |
| SCHEMBL2028516 | 0.84 | SLC7A5 (0.50) | KDM4EPTGS2 | |
| SCHEMBL22346275 | 0.82 | MDM2 (0.45) | GAAMDM2TAAR1ROCK2ROCK1 | |
| SCHEMBL22346276 | 0.82 | MDM2 (0.45) | GAAMDM2TAAR1ROCK2ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 167 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240158445-A1 | CYCLIC CELL-PENETRATING PEPTIDES WITH THREE OR MORE HYDROPHOBIC RESIDUES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-05-16 | — | — | US | claimed |
| EP-4294820-A1 | CYCLIC CELL-PENETRATING PEPTIDES WITH THREE OR MORE HYDROPHOBIC RESIDUES | Ohio State Innovation Foundation (US) | 2023-12-27 | — | — | EP | claimed |
| WO-2022178379-A1 | CYCLIC CELL-PENETRATING PEPTIDES WITH THREE OR MORE HYDROPHOBIC RESIDUES | OHIO STATE INNOVATION FOUNDATION (US) | 2022-08-25 | — | — | WO | claimed |
| US-8778871-B2 | Metastin derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-07-15 | — | — | US | claimed |
| US-20110212890-A1 | METASTIN DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-09-01 | — | — | US | claimed |
| US-20110118172-A1 | METASTIN DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-05-19 | — | — | US | claimed |
| EP-2314609-A1 | METASTIN DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2011-04-27 | — | — | EP | claimed |
| US-20110059888-A1 | METASTIN DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-03-10 | — | — | US | claimed |
| EP-2277900-A1 | METASTIN DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2011-01-26 | — | — | EP | claimed |
| US-20090298765-A1 | Metastin derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-12-03 | — | — | US | claimed |
| EP-2113513-A2 | Metastin derivatives and use thereof | Takeda Pharmaceutical Company Limited (JP) | 2009-11-04 | — | — | EP | claimed |
| US-20090215700-A1 | Metastin derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-08-27 | — | — | US | claimed |
| EP-2081955-A1 | METASTIN DERIVATIVES AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2009-07-29 | — | — | EP | claimed |
| US-20080312155-A1 | Metastin Derivatives and Use Thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-12-18 | — | — | US | claimed |
| WO-2008050897-A1 | METASTIN DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-05-02 | — | — | WO | claimed |
| EP-1758932-A2 | METASTIN DERIVATIVES AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2007-03-07 | — | — | EP | claimed |
| WO-2006001499-A2 | METASTIN DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-01-05 | — | — | WO | claimed |
| US-20260125426-A1 | CYCLIC CELL-PENETRATING PEPTIDES AND USES THEREOF | OHIO STATE INNOVATION FOUNDATION (US) | 2026-05-07 | — | — | US | disclosed |
| EP-0457195-A2 | Peptides having endothelin antagonist activity, a process for preparation thereof and pharmaceutical compositions comprising the same | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1991-11-21 | — | — | EP | disclosed |
| EP-0301850-A2 | LHRH antagonist analogs and 19-nor-progestational steroids for therapy | SYNTEX (U.S.A.) INC. (US) | 1989-02-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215700-A1 | Metastin derivatives and use thereof | SHBG, GNRHR, INHA | GAA 2465/4885MDM2 172/4885TAAR1 4595/4885 |
| US-20080312155-A1 | Metastin Derivatives and Use Thereof | GNRHR, SHBG, MEN1 | GAA 2159/4885MDM2 104/4885TAAR1 4661/4885 |
| US-20110059888-A1 | METASTIN DERIVATIVES AND USE THEREOF | SHBG, GNRHR, INHA | GAA 2465/4885MDM2 172/4885TAAR1 4595/4885 |
| US-20260125426-A1 | CYCLIC CELL-PENETRATING PEPTIDES AND USES THEREOF | SLC7A1, TAP1, SLC7A5 | GAA 4386/4885MDM2 3495/4885TAAR1 1663/4885 |
| US-20110118172-A1 | METASTIN DERIVATIVE AND USE THEREOF | GNRHR, SHBG, INHA | GAA 1613/4885MDM2 246/4885TAAR1 4794/4885 |
| US-20090298765-A1 | Metastin derivatives and use thereof | GNRHR, SHBG, MEN1 | GAA 2159/4885MDM2 104/4885TAAR1 4661/4885 |
| US-20110212890-A1 | METASTIN DERIVATIVE AND USE THEREOF | GNRHR, SHBG, LHCGR | GAA 974/4885MDM2 308/4885TAAR1 4628/4885 |
| US-20240158445-A1 | CYCLIC CELL-PENETRATING PEPTIDES WITH THREE OR MORE HYDROPHOBIC RESIDUES | SLC3A2, SLC7A1, ARGLU1 | GAA 2356/4885MDM2 4340/4885TAAR1 4280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.